Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing

Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) has announced significant adoption of its MSK-ACCESS® and MSK-IMPACT® cancer testing applications powered by SOPHiA DDM™. Thirty-seven prominent institutions globally have adopted these recently launched Liquid Biopsy and Solid Tumor applications, with thirty-four specifically choosing MSK-ACCESS® within ten months of its launch.

Notable adopters include Heidelberg University Hospital, Hospital del Mar, Jewish General Hospital, and the Jiménez Díaz Foundation. The decentralized deployment enables institutions to conduct world-renowned testing in-house, offering less-invasive options for patients with potentially lower costs and faster turnaround times.

This milestone follows SOPHiA GENETICS' 2023 partnership with Memorial Sloan Kettering Cancer Center and their October 2024 agreement with AstraZeneca to accelerate MSK-ACCESS® deployment globally. The company launched MSK-IMPACT® for Solid Tumor testing in November 2024.

Positive

• Rapid adoption with 37 prominent institutions implementing the technology
• 34 institutions specifically adopted MSK-ACCESS® within 10 months of launch
• Strategic partnership with AstraZeneca to accelerate global deployment
• Decentralized testing enables lower costs and faster turnaround times

Negative

• None.

Insights

Healthcare Technology Analyst

The rapid adoption of SOPHiA GENETICS' MSK testing applications represents a significant strategic advancement in the $7.8 billion global liquid biopsy market. The securing of 34 institutional partners for MSK-ACCESS® within just 10 months demonstrates exceptional market validation and positions SOPHiA GENETICS as a pivotal player in the precision oncology space.

The partnership ecosystem, particularly with Memorial Sloan Kettering Cancer Center and AstraZeneca, creates a powerful competitive moat. This collaboration model enables SOPHiA GENETICS to leverage MSK's renowned cancer testing capabilities while utilizing AstraZeneca's global commercial infrastructure for accelerated market penetration. The decentralized testing approach offers a compelling value proposition: institutions can maintain control over patient data while reducing costs and turnaround times, creating a sustainable competitive advantage.

The geographic diversity of adopting institutions - spanning Europe, North America, and Asia - suggests strong product-market fit across different healthcare systems. This global footprint is particularly valuable for building a comprehensive real-world data repository, which becomes increasingly valuable with each new institution added to the network. The expanding data ecosystem creates a virtuous cycle: more institutional adoption leads to richer datasets, which in turn enhances the AI capabilities of the SOPHiA DDM™ platform, attracting more users.

The strategic focus on both liquid biopsy (MSK-ACCESS®) and solid tumor testing (MSK-IMPACT®) positions SOPHiA GENETICS to capture a larger share of the oncology testing market. This dual approach allows healthcare providers to offer comprehensive cancer testing solutions, potentially increasing per-institution revenue through broader test utilization.

SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing

BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pioneer in AI healthcare technology and a leader in data-driven medicine, announced a new milestone in the global adoption of its groundbreaking cancer testing applications MSK-ACCESS^® powered with SOPHiA DDM™ and MSK-IMPACT^® powered with SOPHiA DDM™. Thirty-seven prominent institutions, including top researchers and key opinion leaders worldwide, have already adopted the recently launched Liquid Biopsy and Solid Tumor applications.

Professor Umberto Malapelle, Chair of the Predictive Molecular Pathology Laboratory at the Department of Public Health of the University Federico II of Naples, Italy and the Scientific Secretary of the International Society of Liquid Biopsy, championed the new applications to support his research on lung and other cancers.

"When I learned SOPHiA GENETICS was offering applications from MSK on the SOPHiA DDM™ platform, I was really interested in the evaluation of the performance of this test, in particular because I see SOPHiA GENETICS as true collaborators to help pave the way for the future of cancer research," said Professor Malapelle.

"Bringing best-in-class technology to global organizations is crucial to help advance better health care for all. We are proud to work with trailblazers like Professor Malapelle, who are utilizing our technology and the collective power of our network to make strides in the next wave of cancer care," said Ross Muken, President, SOPHiA GENETICS.

Of the thirty-seven institutions adopting MSK solutions, thirty-four have signed on to adopt MSK-ACCESS^® powered with SOPHiA DDM™, just ten months after the Liquid Biopsy application's launch. The decentralized deployment of MSK-ACCESS^® has enabled hospitals and labs across the globe to launch world-renowned Liquid Biopsy testing from within the walls of their own institution, providing patients with a less-invasive option for genomic testing. In many cases, this decentralized testing also results in lower costs and faster turnaround times, while also enabling institutions to retain control of their patients' data for research or other purposes.

Internationally recognized organizations adopting the application include: Heidelberg University Hospital in Germany; Biopticka Laboratory in the Czech Republic; Hospital del Mar and Hospital La Fe in Spain; University Hospital of Nice and Marseille Regional Hospital Center in France; and Jewish General Hospital in Canada.

The complementary solid tumor application, MSK-IMPACT^® powered with SOPHiA DDM™, has also attracted significant interest from leading organizations across the globe, including: the Jiménez Díaz Foundation University Hospital in Spain; the Cyprus Institute of Neurology and Genetics in Cyprus; and Sofiva Genomics in Taiwan.

Memorial Sloan Kettering Cancer Center (MSK) and SOPHiA GENETICS partnered in 2023 with a vision to use the sophisticated technology of the SOPHiA DDM™ Platform to bring MSK's state-of-the-art cancer testing capabilities to precision medicine institutions worldwide. The two leaders launched the Liquid Biopsy test MSK-ACCESS^® powered with SOPHiA DDM™ in April 2024. In October 2024, SOPHiA GENETICS announced a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS^® powered with SOPHiA DDM™, aiming to increase the availability of this innovative Liquid Biopsy solution worldwide. In November 2024, SOPHiA GENETICS announced the launch of the complementary Solid Tumor test, MSK-IMPACT^® powered with SOPHiA DDM™. These collaborations have the potential to transform cancer research as they enable healthcare providers to draw from a continuously evolving base of real-world data and gain insights from diverse populations while using best-in-class technology.

Join us on Tuesday, February 25, 2025, at 11:00 a.m. (11:00) EDT / 5:00 p.m. (17:00) CET for the Precision Oncology Showcase, a virtual webinar which will spotlight the transformative potential of decentralized, AI-driven technologies for the advancement of cancer care.  

About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

Memorial Sloan Kettering (MSK) has institutional financial interests related to SOPHiA GENETICS.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to the company's management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company's filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company's expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/leading-healthcare-institutions-adopt-msk-access-for-liquid-biopsy-testing-302383208.html

SOURCE SOPHiA GENETICS

FAQ

How many institutions have adopted SOPHiA GENETICS' MSK-ACCESS® testing platform as of February 2025?

34 institutions have adopted MSK-ACCESS® powered with SOPHiA DDM™ within ten months of its launch.

What are the benefits of SOPHiA GENETICS' decentralized testing approach for hospitals?

The decentralized approach allows hospitals to conduct testing in-house, resulting in lower costs, faster turnaround times, and retention of patient data control.

When did SOPHiA GENETICS (SOPH) partner with AstraZeneca for MSK-ACCESS® deployment?

SOPHiA GENETICS announced a definitive partnership agreement with AstraZeneca in October 2024.

Which major healthcare institutions have adopted SOPHiA GENETICS' MSK testing solutions?

Notable adopters include Heidelberg University Hospital, Hospital del Mar, Jewish General Hospital, and the Jiménez Díaz Foundation University Hospital.

When did SOPHiA GENETICS launch the MSK-IMPACT® Solid Tumor testing solution?

SOPHiA GENETICS launched MSK-IMPACT® powered with SOPHiA DDM™ for Solid Tumor testing in November 2024.